DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 20564/S-35
NDA 20596/S-34

SUPPLEMENT APPROVAL

ViiV Healthcare Company
Attention: Natasha H. Smith
Regulatory Project Manager
Five Moore Drive, PO Box 13398
Research Triangle Park, NC 27709

Dear Ms. Smith:

Please refer to your Supplemental New Drug Application (sNDA) dated March 31, 2015, received March 31, 2015, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for EPIVIR (lamivudine) tablets, 150 mg, and 300 mg, and EPIVIR (lamivudine) oral solution, 10 mg per mL.

We acknowledge receipt of your amendments dated April 28, 2015, May 13, 2015, August 7, 2015, August 31, 2015, September 10, 2015, September 16, 2015, September 21, 2015, and September 23, 2015.

This "Prior Approval" supplemental new drug application proposes to update the labeling with the following information:

- To update the Box Warning with the addition of severe hepatomegaly with steatosis.
- To revise the information in WARNINGS AND PRECAUTIONS, subsections 5.1, 5.2, 5.3, and 5.4.
- To update the ADVERSE REACTIONS section with information related to immune reconstitution syndrome and fat redistribution.
- To delete drug-drug interaction information for lamivudine plus interferon- and ribavirin- and zalcitabine-based regimens in the DRUG INTERACTIONS section.
- To update the USE IN SPECIFIC POPULATIONS and CLINICAL PHARMACOLOGY, Pharmacokinetics subsection, with impaired renal function and impaired hepatic function information.
- To update the CLINICAL PHARMACOLOGY, Microbiology subsection, with additional information on lamivudine antiviral activity and zidovudine resistance.

- To update the PATIENT COUNSELING INFORMATION section with information on immune reconstitution syndrome.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling text for the package insert, with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf
The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

OPDP Regulatory Project Manager
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion (OPDP)
5901-B Ammendale Road
Beltsville, MD 20705-1266

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf. Information and Instructions for completing the form can be found at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Christian Yoder, Regulatory Project Manager, at (240) 402-9990 or (301) 796-1500.

Sincerely,

{See appended electronic signature page}

Poonam Mishra, MD, MPH
Deputy Director for Safety
Division of Antiviral Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

ENCLOSURE:
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

POONAM MISHRA
09/30/2015